Breast cancer continues to be one of the most researched diseases out there — a sign that it is still highly troubling in global health. Data recently obtained from extensive clinical trial databases identified trends in which research focus areas, geographical distribution of studies, and types of breast cancer under investigation have emerged as a consequence of efforts dedicated to breast cancer.
The United States ranks highest with an impressive 1,481 ongoing clinical trials, which definitely has to do at least in part with the country's strong medical research infrastructure and funding. China trails far behind but not too closely in second place, with 852 trials followed by the United Kingdom with just 252. This regional distribution emphasizes the high level of effort in breast cancer research and places them ahead strategically to fight against breast malignancies worldwide.
| Country | Ongoing Trials |
|
United States |
1,481 |
|
China |
852 |
|
United Kingdom |
252 |
|
France |
235 |
|
Canada |
162 |
Several key drugs dominate current research with Paclitaxel at number one (89 trials), followed by Cyclophosphamide, and Docetaxel each occurring in 86 IBC clinical trails. Capecitabine is also notable being part of 70 trials, alongside Trastuzumab in a total of 68. Novel agents in this context (and the focus of many scientific inquiries aimed at improving their clinical potency and minimizing potential toxicities) are Hsp90 inhibitors.
Triple-negative breast cancer, one of the most severe and difficult-to-treat subtypes, currently has more clinical trials than any other breast cancer type as researchers seek new strategies for combating its rapid growth. Lacking the three most common receptors - estrogen, progesterone and HER2 - that fuel the development of many breast tumors, triple-negative cancer aggressively spreads with no clear therapies to halt its progression. The second most studied breast cancer is HER2-positive tumors, characterized by excessive levels of the HER2 protein driving unrestrained cellular reproduction. The preponderance of effort focused on triple-negative and HER2-positive subtypes underscores the pressing necessity of devising effective management protocols for these especially intractable and life-threatening manifestations of the disease.
While ongoing clinical trials continue yielding crucial data to address pressing scientific questions, they also illuminate promising paths ahead. Geographically, results point toward cross-border partnerships and allocation priorities. Furthermore, attention to prominent medications and hard-to-treat subtypes grants perspective into forthcoming treatment vistas and adapting tactics against this persistent health challenge.
Mapping these fluctuations is key for those in pharmaceutical and healthcare spheres navigating the intricate routes of medication design, oversight processes, and market planning. Alongside this, making sense of varied trial outcomes according to location and ailment characteristics helps optimize coming research and application distribution.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-Up Approach
3.3 Data Validation
3.4 Primary Interviews
4. Global Clinical Trials Landscape
4.1 Overview of Ongoing Clinical Trials
4.2 Geographical Distribution of Research Efforts
5. Analysis of Ongoing Trials by Country
5.1 Detailed Country-wise Breakdown of Ongoing Trials
5.2 Comparative Analysis and Global Hotspots for Breast Cancer Research
6. Drugs Under Investigation
6.1 Profiles of Top Drugs in Current Clinical Trials
6.2 Analysis of Drug Efficacy and Safety Based on Current Data
7. Focus on Breast Cancer Subtypes
7.1 Detailed Analysis of Trials Focusing on Triple Negative and HER2-positive Breast Cancers
7.2 Trends and Outcomes in Targeting Specific Subtypes
8. Clinical Trial Phases Breakdown
8.1 Phase-wise Distribution of Ongoing Trials
8.2 Insights into Progression and Focus of Research Across Different Phases
9. Regulatory Landscape and Impact
9.1 Overview of Global Regulatory Frameworks Affecting Clinical Trials
9.2 Impact of Regulations on Trial Designs and Market Entry
10. Market Analysis
10.1 Market Size and Forecast (2022-2032)
10.2 Impact of Clinical Trial Outcomes on Market Dynamics
11. Future Outlook and Predictions
11.1 Predictive Analysis Based on Current Trials and Historical Data
11.2 Potential Future Trends and Breakthroughs in Treatment
12. Strategic Recommendations
12.1 Insights for Stakeholders in the Pharmaceutical and Healthcare Sectors
12.2 Recommendations Based on Current Trends and Market Needs
13. Appendix
13.1 Glossary of Terms
13.2 List of Abbreviations
13.3 References and Data Sources
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
